Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438318 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03438318 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT03438318, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
Interventions
- DRUG Atezolizumab
- RADIATION Radiation Therapy
- DRUG CMP-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438318
The ClinicalTrials.gov registry entry for NCT03438318 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03438318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03438318 about?
NCT03438318 is a clinical study titled "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer". This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
What is the current status of trial NCT03438318?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-03-15. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT03438318?
The interventions under investigation include: Atezolizumab (DRUG), Radiation Therapy (RADIATION), CMP-001 (DRUG).
Who is sponsoring clinical trial NCT03438318?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.